A study conducted in Taiwan is the first to show that hyperuricemia is as risky as diabetes in contributing to ESKD and death risk in patients with stage 3 to 5 CKD.
Investigators focused on the prognostic value of the uremic solutes asymmetric dimethylarginine, symmetric dimethylarginine, and trimethylamine-N-oxide.
Atrasentan lowers the risk for a composite of kidney failure, doubling of serum creatinine, or kidney death consistently across subgroups of urinary albumin-creatinine ratio and estimated glomerular filtration rate.